Tuis300601 • SHE
add
Shenzhen Kangtai Biological Prods Co Ltd
Vorige sluiting
¥15,59
Dagwisseling
¥15,31 - ¥15,67
Jaarwisseling
¥13,10 - ¥21,12
Markkapitalisasie
17,49 mjd CNY
Gemiddelde volume
12,41 m
P/V-verhouding
-
Dividend-opbrengs
0,58%
Primêre beurs
SHE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 671,38 m | -17,74% |
Bedryfskoste | 425,29 m | -2,76% |
Netto inkomste | 11,62 m | -93,74% |
Netto winsgrens | 1,73 | -92,40% |
Wins per aandeel | — | — |
EBITDA | 212,79 m | -40,14% |
Effektiewe belastingkoers | -3 472,08% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,65 mjd | 431,20% |
Totale bates | 14,13 mjd | -2,63% |
Totale aanspreeklikheid | 4,52 mjd | -5,87% |
Totale ekwiteit | 9,61 mjd | — |
Uitstaande aandele | 1,12 mjd | — |
Prys om te bespreek | 1,81 | — |
Opbrengs op bates | 2,39% | — |
Opbrengs op kapitaal | 2,94% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 11,62 m | -93,74% |
Kontant van bedrywe | 286,87 m | 60,54% |
Kontant van beleggings | 676,05 m | 357,44% |
Kontant van finansiering | -44,23 m | -4,17% |
Netto kontantverandering | 918,51 m | 825,91% |
Beskikbare kontantvloei | -1,08 mjd | 43,85% |
Meer oor
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
Gestig
08 Sep. 1992
Webwerf
Werknemers
1 913
